Skip to main content
padlock icon - secure page this page is secure

Ototoxic eardrops and tympanic membrane perforations: Time for a change?

Buy Article:

$59.00 + tax (Refund Policy)


Until recently the only available antibiotic eardrops for treatment of the discharging middle ear and mastoid cavity have been potentially ototoxic. With the advent of non-ototoxic fluoroquinolone eardrops, consensus panels in the USA, Canada and the UK have advocated the preferential use of these agents in the open middle ear. However, in Australia, no fluoroquinolone topical agent is approved for use with tympanic membrane perforations, and when used as an ‘off label’ eardrop, none is on the Pharmaceutical Benefits Scheme. This creates an ethical dilemma, particularly with best practice management of chronic suppurative otitis media in indigenous children. Despite concerns regarding resistance issues with ototopical use of systemic antibiotics, bacterial resistance has not been documented in major studies. For equity and ethical reasons, Australian regulatory authorities should consider approving a sterile non-ototoxic eardrop for use in the open middle ear.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: aminoglycosides; eardrops; fluoroquinolones; otorrhoea; ototoxicity

Document Type: Research Article

Affiliations: Department of Pediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia

Publication date: August 1, 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more